Holen Sie sich die Stockscreener-App
79.03
1.97%
1.53
Handel nachbörslich:
79.03
Kymera Therapeutics Inc Aktie (KYMR) Neueste Nachrichten
Kymera at Barclays Conference: Strategic Focus on Immunology By Investing.com - Investing.com Canada
Kymera Therapeutics CFO presents new immunology strategy at Barclays Healthcare Conference - Traders Union
Kymera Therapeutics, Inc. $KYMR Holdings Trimmed by Atika Capital Management LLC - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 25,758 Shares - MarketBeat
Hedge Fund Moves: Can Kymera Therapeutics Inc weather a recessionVolume Spike & Daily Chart Pattern Signals - baoquankhu1.vn
Kymera to present atopic dermatitis trial data at AAD meeting By Investing.com - Investing.com Canada
Kymera at Leerink Global Healthcare: Strategic Insights on Drug Development By Investing.com - Investing.com Canada
KYMR: KT-621 shows strong early efficacy and safety; pivotal Phase 2b readouts expected in 2027 - TradingView
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology Annual Meeting - Investing News Network
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting - Bitget
Experimental atopic dermatitis pill KT-621 heads to late-breaking AAD stage - Stock Titan
A Look At Kymera Therapeutics (KYMR) Valuation After Equity Raise, Wider Losses And Leadership Change - Sahm
Kymera CEO Nello Mainolfi’s Boldest Line Had Nothing to Do With the Earnings Miss - Yahoo Finance
Market Moves: What is the long term forecast for Kymera Therapeutics Inc. stockWeekly Profit Report & Safe Capital Growth Plans - baoquankhu1.vn
How (KYMR) Movements Inform Risk Allocation Models - Stock Traders Daily
Kymera Therapeutics (NASDAQ:KYMR) Lowered to Sell Rating by Wall Street Zen - MarketBeat
Profit Recap: How sensitive is Kymera Therapeutics Inc to inflationWeekly Volume Report & Reliable Entry Point Trade Alerts - baoquankhu1.vn
JPMorgan Chase & Co. Has $10.91 Million Stock Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
Q1 EPS Estimate for Kymera Therapeutics Boosted by Analyst - MarketBeat
Kymera (KYMR) Q4 2025 Earnings Call Transcript - AOL.com
Kymera Therapeutics (NASDAQ:KYMR) COO Jeremy Chadwick Sells 3,919 Shares - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CFO Sells 4,895 Shares of Stock - MarketBeat
Kymera Stock Up 130% as $135 Million Buy Boosts Immunology Bet - AOL.com
Bruce Jacobs Sells 7,576 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Jared Gollob Sells 5,613 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock - MarketBeat
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 81,866 Shares of Stock - MarketBeat
Kymera Therapeutics, Inc. $KYMR Shares Acquired by Rafferty Asset Management LLC - MarketBeat
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $128.00 - MarketBeat
UBS Raises Price Target for Kymera Therapeutics (KYMR) to $128 | - GuruFocus
Kymera at TD Cowen Conference: Strategic Insights on Drug Programs - Investing.com
Commit To Purchase Kymera Therapeutics At $60, Earn 15.1% Annualized Using Options - Nasdaq
How Kymera’s Bigger Losses and New Equity Plans May Impact Kymera Therapeutics (KYMR) Investors - simplywall.st
Kymera Therapeutics (KYMR) Stock Analysis: Exploring a 30% Upside Potential Amid Biotech Innovation - DirectorsTalk Interviews
UBS Adjusts Price Target on Kymera Therapeutics to $128 From $90, Maintains Buy Rating - marketscreener.com
Kymera Therapeutics: Well-Funded Pipeline Enters A Defining Clinical Phase (NASDAQ:KYMR) - Seeking Alpha
Kairos Pharma signs deal for Celyn Therapeutics’ CL-273 - Pharmaceutical Technology
Citigroup Raises Kymera Therapeutics (NASDAQ:KYMR) Price Target to $120.00 - MarketBeat
Kymera Therapeutics (KYMR): Citigroup Raises Price Target, Reaff - GuruFocus
Stephens raises Kymera Therapeutics price target to $100 on pipeline By Investing.com - Investing.com Canada
Kymera Therapeutics (KYMR): Analyst Raises Price Target to $100 | KYMR Stock News - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Price Target Raised to $100.00 at Stephens - MarketBeat
TD Asset Management Inc Reduces Holdings in Kymera Therapeutics, Inc. $KYMR - MarketBeat
The Bull Case For Kymera Therapeutics (KYMR) Could Change Following Wider Losses And Major Equity Plans - Yahoo Finance
Kymera Therapeutics Pivots to Immunology, Highlights KT-621 Data, Starts IRF5 Dosing; Runway to 2029 - MarketBeat
Kymera Therapeutics Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Vanguard Group Inc. Cuts Stake in Kymera Therapeutics, Inc. $KYMR - MarketBeat
KYMR Should I Buy - Intellectia AI
Kymera Therapeutics (KYMR) TTM Loss Of US$311 Million Tests Bullish Growth Narrative - simplywall.st
Kymera Therapeutics Signals Strong Momentum In Earnings Call - TipRanks
Kymera Therapeutics, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:KYMR) 2026-02-27 - Seeking Alpha
Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors - TipRanks
Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway - Finviz
Kymera Therapeutics advances oral degrader pipeline amid immunology research momentum - Traders Union
Kymera Therapeutics price target raised to $140 from $125 at Piper Sandler - Yahoo Finance
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q4 2025 Earnings Call Transcript - Insider Monkey
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus
Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results - MarketBeat
Kymera Therapeutics launches $500 million at-the-market stock offering - Investing.com Australia
Kymera Therapeutics launches $500 million at-the-market stock offering By Investing.com - Investing.com Canada
KYMR: Kymera Therapeutics Maintained Outperform by RBC Capital Feb 26 2026 - Meyka
Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: Strategic Collaborations and ... By GuruFocus - Investing.com Canada
Kymera Therapeutics Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Kymera Misses Q4 2025 Forecasts, Stock Drops - Investing.com
Morgan Stanley cuts Kymera Therapeutics stock price target on pipeline progress - Investing.com UK
Kymera Therapeutics Inc (KYMR) Q4 2025 Earnings Call Highlights: - GuruFocus
Kymera at Oppenheimer Conference: Strategic Focus on IMiD and Clinical Progress - Investing.com Canada
BTIG Maintains Buy Rating on KYMR, Lowers Price Target | KYMR St - GuruFocus
Analyst Expectations For Kymera Therapeutics's Future - Benzinga
KYMR: STAT6 and IRF5 programs advance with strong data, targeting major unmet needs in immunology - TradingView
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):